We have evaluated the post-embolization findings of hepatic tumors(15 cases of hepatoma, and 5 cases ofmetastatic tumors)using Ivalon particles in conjunction with the pre-embolization status of CT. Serial CTexaminations were done every 3 week intervals after embolization procedure. Findings were as follows: 1. Inhepatoma, tumor volume was decreased in 7 cases at 3 week after procedure. Among which 5 cases revealed tumorvolume decrease of 0 to 25 percent. 2. Most important findings of post embolized hepatic tumors was decreasedtumoral density and attenuation of tumor wall enhancement. 3. Intratumoral air was developed within 3 week afterembolization and appeared as mottled or linear branching patterns in the center or periphery of the tumor. 4. Itseems to be important to observe the change of intratumoral density and measurement of tumoral volume to determinethe reembolizatin procedure.
Carcinoma, Hepatocellular ; Tumor Burden

No abstract available.
Humans ; Ovarian Neoplasms ; Tumor Burden

PURPOSE: .In FSRT (Fractionated stereotactic radiotherapy) planning, we studied the usefulness between multiple arc FSRT and conformal FSRT by comparing tumor shape and DVH(dose volume histogram). MATERIALS AND METHDS: In Chungnam Univ. hospital, we had treated the sixteen patients with FSRT from Aug. 1997 to Dec. 1998. In choosing multiple arc FSRT or conformal FSRT, we had considered multiple arc FSRT if tumor shape was similar to sphere or the value of IF was less than 1.25, conformal FSRT if tumor shape was very irregular or IF was more than 1.3. For evaluation of treatment planning, we had considered the appropriate DVH for tumor volume and for critical organs. RESULT: The errors between reference point and the coordinates point on AP, Lat radiography were less than 1 mm before treatment. We had planned 3~5 arcs for multiple arc FSRT, 5~6pots for conformal FSRT. The mean dose distribution of tumor volume of cumulative DVH between multiple arc FSRT and conformal FSRT was 90.6, 86%, respectively. The dose of critical organs irradiated was less than 5% maximum dose of cumulative DVH. CONCLUSION: We had obtained the similar value between multiple arc FSRT and conformal FSRT, so that we had appropriate treatment planning of FSRT for multiple arc FSRT and conformal FSRT according to tumor shape and size.
Chungcheongnam-do ; Humans ; Radiography ; Tumor Burden

The optimal management of uveal melanoma is still a matter of controversy. To determine the effect of Gamma Knife surgery on patients with uveal melanoma, the authors reviewed the outcome of five operations performed between September 1993 and August 1996. The mean age of the patients was 60.7(range 42 to 76) years; the median follow-up period was 10 months, and four patients were followed up for more than 6 months. The mean tumor volume was 3442mm3(mean diameter 15.3mm) and all patients were irradiated with a mean maximum dose of 74Gy (range 60-80Gy), using a 50% isodose on the tumor margin. In one patient, the tumor disappeared completely 32 months after Gamma Knife surgery; because the tumor did not regress, one patient subsequently required enucleation, and two remained stable. During a mean follow-up period of 10 months, vision was preserved in two patients, but one went blind; in one, enucleation was performed because the tumor did not regress. These results suggest that in cases of uveal melanoma Gamma Knife surgery can effectively control local tumors, can spare the eyeball, and may prevent loss of vision.
Follow-Up Studies ; Humans ; Melanoma* ; Tumor Burden

Serum prostatic specific antigen (PSA) will be elevated in cases of BPH, prostatitis, prostatic cancer, and other conditions of prostate. Generally PSA is proportional to increased the size of the transitional zone of the prostate, but the PSA production by malignant glands is variable PSA production is depend on the degree of histologic differentiation in case of prostate cancer, with well-differentiated glands producing more PSA and undifferentiated cancer producing less PSA. Significant elevations of PSA, greater than 10 to 20 ng/ml, in the absence of prostatitis, or recent prostatic biopsy are strongly suggestive of cancer of the prostate. Several large scale studies have demonstrated that serum PSA correlates well with advancing clinical stage, tumor volume and pathological stage. We report a case in which high stage and poorly differentiated pathologic grade prostate cancer with low serum PSA level.
Biopsy ; Prostate* ; Prostatic Neoplasms* ; Prostatitis ; Tumor Burden

Thalidomide is an anti-angiogenic agent widely used in patients with multiple myeloma. The response to therapy is commonly monitored using serum and/or urine M protein, as these are known to reflect the tumor burden. Although extramedullary plasmacytomas are tissues with high neovascularization, it has been suggested in some reports that the response to thalidomide in these patients may be inferior, despite changes in the serum M protein level. Herein, we report the case of a patient who newly developed hepatosplenic extramedullary plasmacytoma, despite reduction in the serum M protein level following thalidomide treatment.
Humans ; Multiple Myeloma* ; Plasmacytoma ; Thalidomide* ; Tumor Burden

Successful anticancer strategies require a differential response between tumor and normal tissue (i.e., a therapeutic ratio). In fact, improving the effectiveness of a cancer therapeutic is of no clinical value in the absence of a significant increase in the differential response between tumor and normal tissue. Although radiation dose escalation with the use of intensity modulated radiation therapy has permitted the maximum tolerable dose for most locally advanced cancers, improvements in tumor control without damaging normal adjacent tissues are needed. As a means of increasing the therapeutic ratio, several new approaches are under development. Drugs targeting signal transduction pathways in cancer progression and more recently, immunotherapeutics targeting specific immune cell subsets have entered the clinic with promising early results. Radiobiological research is underway to address pressing questions as to the dose per fraction, irradiated tumor volume and time sequence of the drug administration. To exploit these exciting novel strategies, a better understanding is needed of the cellular and molecular pathways responsible for both cancer and normal tissue and organ response, including the role of radiation-induced accelerated senescence. This review will highlight the current understanding of promising biologically targeted therapies to enhance the radiation therapeutic ratio.
Aging ; Radiobiology ; Radioimmunotherapy ; Signal Transduction ; Tumor Burden

Background: PSMA-targeted radiopharmaceuticals have been widely studied for their theragnostic role in prostate cancer and were introduced in the Philippines in 2018. The optimal administered activity of 177Lu-PSMA for targeted endoradiotherapy has not yet been established and is thought to be influenced by several factors, including tumor burden. This study investigates the effect of tumor burden on the normal tissue PSMA uptake among Filipino patients with prostate cancer using its diagnostic counterpart, 68Ga-PSMA I&T Methods: One hundred four patients imaged with 68Ga-PSMA I&T PET/CT in our institution from January 2018 to May 2020 were included. Patients were visually classified into low, medium, and high tumor burden groups. Maximum and mean standardized uptake values (SUVmax and SUVmean) of the lacrimal glands, parotid glands, submandibular glands, kidneys, liver, spleen, and bone were measured and compared among tumor burden groups. Results and Conclusions 68Ga-PSMA I&T uptake in the kidneys, the salivary glands, and the liver, were significantly reduced by approximately 25-50% in patients with high tumor burden. This finding supports the hypothesis that patients with higher tumor load can tolerate higher activity doses of 177Lu-PSMA for endoradiotherapy before developing significant damage to the critical organs. This may serve as a guide towards optimizing and personalizing 177Lu-PSMA I&T administered activity dose for radionuclide therapy
Positron-Emission Tomography ; Prostatic Neoplasms ; Tumor Burden

We evaluated the effect of nicotinamide on cellular O2 consumption and metabolic status i.e., adenylate phosphates and NAD+ in-vitro, and changes in blood flow in-vivo, to determine whether changes in cellular metabolism or increased oxygen availability, was responsible for increased tumor oxygenation. Thirty min. Pre-incubation of cells with~4mM (=500mg/kg) nicotinamide resulted in no change in cellular O2 consumption. Similarly, neither the adenylate phosphates nor the cellular NAD+ levels were altered in the presence of~4mM nicotinamide. In-vivo, nicotinamide (500mg/kg) increased O2availability as estimated by changes in relative tumor blood flow (RBC flux). The changes in RBC flux measured by the laser Doppler method, were tumor volume dependent and increased from~35% in~150mmdegree tumors to~75% in~500mmdegree tumors. In conclusion, these observations indicate a reduction in local tissue O2 consumption is not a mechanism of improved tumor oxygenation by nicotinamide in FsaII murine tumor model. The primary mechanism of increased pO2 appears to be an increased local tumor blood flow.
Laser-Doppler Flowmetry ; Metabolism ; Niacinamide ; Oxygen ; Phosphates ; Tumor Burden

PURPOSE: To determine whether large rectal volume on planning computed tomography (CT) results in lower tumor regression grade (TRG) after neoadjuvant concurrent chemoradiotherapy (CCRT) in rectal cancer patients. MATERIALS AND METHODS: We reviewed medical records of 113 patients treated with surgery following neoadjuvant CCRT for rectal cancer between January and December 2012. Rectal volume was contoured on axial images in which gross tumor volume was included. Average axial rectal area (ARA) was defined as rectal volume divided by longitudinal tumor length. The impact of rectal volume and ARA on TRG was assessed. RESULTS: Average rectal volume and ARA were 11.3 mL and 2.9 cm². After completion of neoadjuvant CCRT in 113 patients, pathologic results revealed total regression (TRG 4) in 28 patients (25%), good regression (TRG 3) in 25 patients (22%), moderate regression (TRG 2) in 34 patients (30%), minor regression (TRG 1) in 24 patients (21%), and no regression (TRG0) in 2 patients (2%). No difference of rectal volume and ARA was found between each TRG groups. Linear correlation existed between rectal volume and TRG (p = 0.036) but not between ARA and TRG (p = 0.058). CONCLUSION: Rectal volume on planning CT has no significance on TRG in patients receiving neoadjuvant CCRT for rectal cancer. These results indicate that maintaining minimal rectal volume before each treatment may not be necessary.
Chemoradiotherapy* ; Humans ; Medical Records ; Rectal Neoplasms* ; Tumor Burden